Vasopressin: A look at dialysis hypertension and autonomic dysfunction

Kidney International

Volumn 71, Issue 4, 2007, Pages 285-287

  Flanigan, M J ^a,b  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b MARSHFIELD CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VASOPRESSIN;

AUTOCRINE EFFECT; AUTONOMIC DYSFUNCTION; CARDIOVASCULAR FUNCTION; DIALYSIS; DRUG ANTAGONISM; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; HUMAN; HYPERTENSION; HYPOTENSION; NEUROENDOCRINE SYSTEM; PRIORITY JOURNAL; REVIEW; UREMIA; VASCULAR RESISTANCE;

EID: 33846885192     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002114     Document Type: Note

References (22)

1. Bianchi G. Hypertension in chronic renal failure and end-stage renal disease patients treated with haemodialysis or peritoneal dialysis. Nephrol Dial Transplant 2000; 15(Suppl 5): 105-110.
2. Mortality and Causes of Death. Table H.29. United States Renal Data System. 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA, 2005.
3. van der Zee S, Thompson A, Zimmerman R et al. Vasopressin administration facilitates fluid removal during hemodialysis. Kidney Int 2007; 71: 318-324.
4. Friess U, Rascher W, Ritz E, Gross P. Failure of arginine-vasopressin and other pressor hormones to increase in severe recurrent dialysis hypotension. Nephrol Dial Transplant 1995; 10: 1421-1427.
5. Iimura O, Tabei K, Nagashima H, Asano Y. A study on regulating factors of plasma refilling during hemodialysis. Nephron 1996; 74: 19-25.
6. Toshimizu T, Nasa Y, Tanoue A et al. V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity. Proc Natl Acad Sci USA 2006; 103: 7807-7812.
7. Kielstein JT, Zoccali C. Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age? Am J Kidney Dis 2005; 46: 186-202.
8. Campese VM, Mitra N, Sandee D. Hypertension in renal parenchymal disease: why is it so resistant to treatment? Kidney Int 2006; 69: 967-973.
9. Ventura RR, Gomes DA, Reis WL et al. Nitrergic modulation of vasopressin, oxytocin and atrial natriuretic peptide secretion in response to sodium intake and hypertonic blood volume expansion. Braz J Med Biol Res 2002; 35: 1101-1109.
10. Neumann J, Ligtenberg G, Klein II et al. Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. Kidney Int 2004; 65: 1568-1576.
11. Klein K, Daschner M, Vogel M et al. Impaired autofeedback regulation of hypothalamic norepinephrine release in experimental uremia. J Am Soc Nephrol 2005; 16: 2081-2087.
12. Rubinger D, Revis N, Pollak A et al. Predictors of haemodynamic instability and heart rate variability during haemodialysis. Nephrol Dial Transplant 2004; 19: 2053-2060.
13. Iimura O, Tabei K, Nagashima H, Asano Y. A study on regulating factors of plasma refilling during hemodialysis. Nephron 1996; 74: 19-25.
14. Thuraisingham RC, Yaqoob MM. Oxidative consumption of nitric oxide: a potential mediator of uremic vascular disease. Kidney Int Suppl 2003; S29-S32.
15. Xu J, Li G, Wang P et al. Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J Clin Invest 2005; 115: 1275-1280.
16. DiBona GF. The sympathetic nervous system and hypertension: recent developments. Hypertension 2004; 43: 147-150.
17. DiBona GF. Central angiotensin modulation of baroreflex control of renal sympathetic nerve activity in the rat: influence of dietary sodium. Acta Physiol Scand 2003; 177: 285-289.
18. Shoji T, Tsubakihara Y, Fujii M, Imai E. Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int 2004; 66: 1212-1220.
19. Chan CT, Jain V, Picton P et al. Nocturnal hemodialysis increases arterial baroreflex sensitivity and compliance and normalizes blood pressure of hypertensive patients with end-stage renal disease. Kidney Int 2005; 68: 338-344.
20. Chan CT, Hanly P, Gabor J et al. Impact of nocturnal hemodialysis on the variability of heart rate and duration of hypoxemia during sleep. Kidney Int 2004; 65: 661-665.
21. Chan CT, Harvey PJ, Picton P et al. Short-term blood pressure, noradrenergic, and vascular effects of nocturnal home hemodialysis. Hypertension 2003; 42: 925-931.
22. Chan CT, Harvey PJ, Boger R et al. Dissociation between the short-term effects of nocturnal hemodialysis on endothelium dependent vasodilation and plasma ADMA. Arterioscler Thromb Vasc Biol 2005; 25: 2685-2686.